Johnson & Johnson Publishes Interim Results of Single-Shot COVID-19 Vaccine in P-I/IIa Sub-Study for COVID 19 in NEJM

July 15, 2021 Auto Bot Clinical Trials 0

Shots:

  • The ongoing P-I/IIa sub-study involves evaluating safety, reactogenicity & immunogenicity of COVID-19 vaccine (IM, given as single-dose or two-dose, 8 wks. apart) in adults across multiple clinical sites in Belgium & the US
  • The results demonstrated durable humoral & cellular immune responses in single-shot COVID-19 vaccine @8mos. after immunization & elicits neutralizing Ab activity against Delta variant (B.1.617.2) & other SARS-CoV-2 variants of concern
  • The results from a new analysis of blood samples in the P-III ENSEMBLE study showed that the single-shot COVID-19 vaccine, induced neutralizing Ab activity against the Delta variant at a higher level

Click here to read full press release/ article | Ref: J&J | Image: Actualidad RT

The post Johnson & Johnson Publishes Interim Results of Single-Shot COVID-19 Vaccine in P-I/IIa Sub-Study for COVID 19 in NEJM first appeared on PharmaShots.